Abeona Therapeutics (ABEO) Expected to Post Earnings on Wednesday

Abeona Therapeutics (NASDAQ:ABEO) is anticipated to issue its Q3 2026 results before the market opens on Wednesday, November 11th. Analysts expect the company to post earnings of ($0.14) per share and revenue of $14.82 million for the quarter. Investors can check the company’s upcoming Q3 2026 earnings results page for the latest details on the call scheduled for Wednesday, November 11, 2026 at 8:30 AM ET.

Abeona Therapeutics (NASDAQ:ABEO) last announced its quarterly earnings data on Thursday, August 13th. The biopharmaceutical company reported ($0.35) earnings per share for the quarter, missing the consensus estimate of ($0.23) by ($0.12). The company had revenue of $11.38 million during the quarter, compared to the consensus estimate of $12.24 million. On average, analysts expect Abeona Therapeutics to post ($0.88) EPS for the current fiscal year and ($0.14) EPS for the next fiscal year.

Abeona Therapeutics Stock Performance

NASDAQ:ABEO traded up $0.01 on Wednesday, reaching $4.26. 41,097 shares of the company’s stock were exchanged, compared to its average volume of 1,249,560. The company has a debt-to-equity ratio of 0.01, a current ratio of 6.63 and a quick ratio of 6.40. The firm has a market cap of $243.87 million, a price-to-earnings ratio of -3.92 and a beta of 1.50. Abeona Therapeutics has a 52 week low of $4.00 and a 52 week high of $7.65. The stock has a fifty day simple moving average of $5.17 and a 200-day simple moving average of $5.48.

Analyst Upgrades and Downgrades

A number of research firms have recently commented on ABEO. Oppenheimer reaffirmed an “outperform” rating and issued a $21.00 price target (down from $22.00) on shares of Abeona Therapeutics in a report on Friday, August 14th. Roth Capital began coverage on Abeona Therapeutics in a report on Thursday, September 17th. They set a “buy” rating and a $17.00 price objective on the stock. Weiss Ratings downgraded Abeona Therapeutics from a “sell (d+)” rating to a “sell (d)” rating in a research note on Monday, August 17th. HC Wainwright restated a “buy” rating on shares of Abeona Therapeutics in a research note on Friday, September 25th. Finally, Wall Street Zen raised shares of Abeona Therapeutics from a “strong sell” rating to a “sell” rating in a report on Saturday, August 1st. Five analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, Abeona Therapeutics presently has an average rating of “Moderate Buy” and an average price target of $21.00.

Insider Transactions at Abeona Therapeutics

In other news, CFO Joseph Vazzano sold 9,191 shares of the stock in a transaction dated Tuesday, September 29th. The stock was sold at an average price of $5.16, for a total transaction of $47,425.56. Following the transaction, the chief financial officer directly owned 482,888 shares in the company, valued at approximately $2,491,702.08. This represents a 1.87% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, SVP Brendan O’Malley sold 6,727 shares of Abeona Therapeutics stock in a transaction that occurred on Tuesday, September 29th. The stock was sold at an average price of $5.16, for a total transaction of $34,711.32. Following the transaction, the senior vice president directly owned 421,226 shares in the company, valued at $2,173,526.16. This trade represents a 1.57% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last ninety days, insiders have sold 55,428 shares of company stock worth $296,508. Company insiders own 7.10% of the company’s stock.

Abeona Therapeutics Company Profile

Abeona Therapeutics Inc (NASDAQ: ABEO) is a biopharmaceutical company focused on developing and commercializing cell and gene therapies for serious and rare genetic diseases. The company’s programs are designed to address conditions with limited treatment options, including diseases caused by genetic defects affecting the skin and other tissues.

Abeona’s lead product, prademagene zamikeracel, is an autologous cell therapy for recessive dystrophic epidermolysis bullosa (RDEB), a rare inherited disorder that causes fragile skin and chronic wounds.